Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LAVA Therapeutics (LVTX)
NASDAQ:LVTX
LAVA Therapeutics (LVTX) Stock Price & Analysis
136 Followers
LVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.13 - $6.47
Previous Close$2.83
Volume103.71K
Average Volume (3M)1.85M
Market Cap
$74.40M
Enterprise Value-$14.86M
Total Cash (Recent Filing)$95.57M
Total Debt (Recent Filing)$6.31M
Price to Earnings (P/E)-1.8
Beta0.60
Next Earnings
May 15, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding26,289,087
10 Day Avg. Volume230,597
30 Day Avg. Volume1,850,688
Standard Deviation0.29
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.48
Price to Sales (P/S)11.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.94
Enterprise Value/Gross Profit-4.52
Enterprise Value/Ebitda1.67
Forecast
1Y Price Target
$6.00Price Target Upside112.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
LAVA Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsLAVA-1207 shows promising signs of efficacy and safety, indicating potential breakthroughs in prostate cancer treatment.
Financial HealthLava Therapeutics maintains a robust cash position, enabling the continuation of its vital research and development activities.
Strategic PartnershipsThe collaboration with Merck to study LAVA-1207 in combination with pembrolizumab could significantly advance treatment options for metastatic castration-resistant prostate cancer.
Bears Say
Drug EfficacyEngaging γδ T-cells alone has not yet been proven to drive clinical benefit with lower risk of toxicity, presenting inherent risk to the read-out.
Drug EfficacyThe question mark over the response durability for single-agent JANX007 indicates a need for further follow-up to assess long-term efficacy.
Drug SafetyThree dose-limiting toxicities observed in the LAVA-1207 and IL-2 combination arm indicate potential safety concerns.
---
Ownership Overview
0.00%
Insiders
2.98% Mutual Funds
0.07% Other Institutional Investors
96.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LVTX FAQ
What was LAVA Therapeutics’s price range in the past 12 months?
LAVA Therapeutics lowest stock price was $1.13 and its highest was $6.47 in the past 12 months.
What is LAVA Therapeutics’s market cap?
Currently, no data Available
When is LAVA Therapeutics’s upcoming earnings report date?
LAVA Therapeutics’s upcoming earnings report date is May 15, 2024 which is in 21 days.
How were LAVA Therapeutics’s earnings last quarter?
LAVA Therapeutics released its earnings results on Mar 20, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.44 by $0.2.
Is LAVA Therapeutics overvalued?
According to Wall Street analysts LAVA Therapeutics’s price is currently Undervalued.
Does LAVA Therapeutics pay dividends?
LAVA Therapeutics does not currently pay dividends.
What is LAVA Therapeutics’s EPS estimate?
LAVA Therapeutics’s EPS estimate is -$0.22.
How many shares outstanding does LAVA Therapeutics have?
LAVA Therapeutics has 26,289,087 shares outstanding.
What happened to LAVA Therapeutics’s price movement after its last earnings report?
LAVA Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.44. Following the earnings report the stock price went down -3.762%.
Which hedge fund is a major shareholder of LAVA Therapeutics?
Among the largest hedge funds holding LAVA Therapeutics’s share is Bruce & Co., Inc.. It holds LAVA Therapeutics’s shares valued at 1M.
---
LAVA Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (112.01% Upside)
$6.00 (112.01% Upside)
Hedge Fund Trend
Decreased
By 1.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.73%
12-Months-Change
Fundamentals
Return on Equity
-61.18%
Trailing 12-Months
Asset Growth
-29.08%
Trailing 12-Months
Company Description
LAVA Therapeutics
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
---
LVTX Stock 12 Months Forecast
Average Price Target
$6.00
▲(112.01% Upside)
Technical Analysis
Best Analysts Covering LVTX
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+15.81%
reiterated a buy rating last month
Copying Reni Benjamin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.81% per trade.
---